Drugs of the Future

Papers
(The TQCC of Drugs of the Future is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
American Association for Cancer Research (AACR) - 113th Annual Meeting. New Orleans/Virtual - April 8-13, 20226
Lisavanbulin. Microtubule destabilizer (tubulin polymerization inhibitor), Tumor checkpoint controller, Treatment of advanced glioblastoma multiforme4
An overview of prophylaxis and treatment indications for COVID-19-related thrombotic complications3
Pipeline on the Move3
Pipeline on the Move2
American Society of Hematology - 64th Annual Meeting and Exposition. New Orleans - December 10-13, 20222
American Academy of Neurology (AAN) - 74th Annual Meeting: The Great Neuro Reunion. Seattle - April 2-7, 20222
NME Digest2
NME Digest2
Therapeutic targets for giant cell arteritis1
IDWeek 2022. Washington, D.C. - October 19-23, 20221
Ancremonam. Monobactam, Treatment of multidrug-resistant Enterobacteriaceae infections1
Experimental and in silico approaches to target selection and tractability for drug discovery. Highlights from the Society for Medicines Research Confer1
NCX-470. Nitric oxide-donating prostaglandin analogue, Treatment of glaucoma, Treatment of ocular hypertension1
Therapeutic targets for dermatomyositis1
Pipeline on the Move1
American Heart Association (AHA) Scientific Sessions - 2022 Annual Meeting. Chicago/Virtual - November 5-7, 20221
Imlunestrant. Selective estrogen receptor degrader (SERD), Treatment of breast cancer1
Pipeline on the Move1
Tanfanercept. Recombinant variant of human TNFR1, TNF-α modulator, Treatment of dry eye disease0
Pipeline on the Move0
Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 20220
BIO-Europe Spring Digital 2022 – 16th Annual Partnering Conference. Virtual – March 28-31, 20220
Tebipenem pivoxil hydrobromide. Penicillin-binding protein (PBP) (bacterial) inhibitor, Carbapenem antibiotic, Treatment of urinary tract infections0
Pipeline on the Move0
Pipeline on the Move0
Gene therapy in the fight against pediatric blood disorders: sickle cell disease and β-thalassemia0
European Association of Nuclear Medicine – 35th Annual Congress. Barcelona – October 15-19, 20220
AACR-NCI-EORTC - 34th International Symposium on Molecular Targets and Cancer Therapeutics. Barcelona - October 26-28, 20220
Lenadogene nolparvovec. rAAV2 gene therapy vector encoding ND4, Treatment of Leber hereditary optic neuropathy0
Cefepime/enmetazobactam. β-Lactam/β-lactamase inhibitor, Treatment of complicated urinary tract infection0
Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity0
European Society of Medical Oncology (ESMO) - 2022 Annual Congress. Paris/Virtual - September 9-13, 20220
Pruxelutamide. Androgen receptor antagonist, Treatment of metastatic castration-resistant prostate cancer, Treatment of metastatic breast cancer0
Tinlarebant. Retinol-binding protein 4 (RBP4) inhibitor, Treatment of Stargardt disease, Treatment of dry age-related macular degeneration0
Navafenterol. Dual M3 receptor antagonist/β2-adrenoceptor agonist (MABA), Treatment of chronic obstructive pulmonary disease0
Efanesoctocog alfa. Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein, Treatment of hemophilia A0
Pipeline on the Move0
Association for Research in Vision and Ophthalmology (ARVO) - 2022 Annual Meeting. Denver/Virtual - May 1-4 and 11-12, 20220
Alzheimer's Association International Conference (AAIC) 2022. San Diego – July 31-August 4, 20220
Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease0
Glofitamab. Anti-CD20 T-cell–engaging bispecific antibody, Treatment of non-Hodgkin lymphoma0
Recent Clinical Disclosures and SMR Award. Highlights from the Society for Medicines Research Conference. Virtual - December 2, 20210
Sabatolimab. TIM-3-targeting monoclonal antibody, Treatment of myelodysplastic syndrome, Treatment of acute myeloid leukemia0
RGX-314. AAV8 gene therapy encoding anti-VEGF Fab, Treatment of wet age-related macular degeneration, Treatment of diabetic retinopathy0
Biomarkers in frontotemporal dementia: a narrative review0
Association for Cancer Immunotherapy (CIMT) - 19th Annual Meeting. Mainz/Virtual - May 10-12, 20220
Tolebrutinib. Bruton tyrosine kinase (BTK) inhibitor, Treatment of multiple sclerosis0
NME Digest0
American Society of Clinical Oncology (ASCO) – 58th Annual Meeting. Chicago/Virtual – June 3-7, 20220
Innovative new pharma and biotech partnerships: How is the landscape transforming? Highlights from the Society for Medicines Research Conference. Steven0
European Respiratory Society - 32nd International Congress. Barcelona - September 4-6, 20220
Cefepime/taniborbactam. Fixed-dose combination, Cephalosporin beta-lactam antibiotic/beta-lactamase inhibitor, Treatment of complicated urinary tract in0
Furaprevir. HCV NS3/4A protease inhibitor, Treatment of chronic hepatitis C virus infection0
Gene therapies for achromatopsia under clinical evaluation0
Society for the Study of Inborn Errors of Metabolism – 2022 Annual Symposium. Freiburg – August 30-September 2, 20220
Taletrectinib adipate. Dual ROS1 and NTRK inhibitor, Treatment of non-small cell lung cancer, Treatment of solid tumors0
Zandelisib. Phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, Treatment of B-cell lymphomas0
The Liver Meeting 2022 - American Association for the Study of Liver Diseases (AASLD). 73rd Annual Meeting. Washington, D.C. - November 4-8, 20220
Tavokinogene telsaplasmid. DNA-based interleukin-12 (IL-12), Gene therapy, Treatment of metastatic melanoma, Treatment of triple-negative breast cancer,0
Adagrasib. GTPase KRAS (G12C mutant) inhibitor, Treatment of non-small cell lung cancer, Treatment of colorectal cancer0
Targets to watch in neuroinflammation: focus on RIPK10
Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity0
Erfonrilimab. Bispecific anti-PD-L1/CTLA-4 antibody, Cancer immunotherapy0
American Society of Gene and Cell Therapy (ASGCT) – 25th Annual Meeting. Washington, D.C./Virtual - May 16-19, 20220
32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Lisbon/Virtual - April 23-26, 20220
American Society for Clinical Pharmacology and Therapeutics – 123rd Annual Meeting. Virtual – March 16-18, 20220
Uproleselan sodium. E-selectin antagonist, Treatment of acute myeloid leukemia0
Lenzilumab. Anti-GM-CSF monoclonal antibody, Treatment of chronic myelomonocytic leukemia, Treatment of COVID-190
Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma0
Crovalimab. Anti-C5 monoclonal antibody, Treatment of paroxysmal nocturnal hemoglobinuria, Treatment of atypical hemolytic uremic syndrome, Treatment of0
American Chemical Society (ACS) – 264th National Meeting and Exposition. Chicago/Virtual – August 21-25, 20220
International Association for the Study of Lung Cancer (IASLC) – 23rd World Conference on Lung Cancer (WCLC 2022). Vienna – August 6-9, 20220
Pipeline on the Move0
European Association for Cancer Research (EACR) – 28th Annual Meeting. Seville – June 20-23, 20220
Sonelokimab. Interleukin-17A and -F nanobody, Treatment of moderate to severe psoriasis, Treatment of hidradenitis suppurativa0
American Chemical Society – 263rd National Meeting and Exposition. Virtual/San Diego – March 20-24, 20220
Society for Immunotherapy of Cancer (SITC) – 37th Annual Meeting. Boston/Virtual – November 8-12, 20220
Repotrectinib. ALK/ROS1/TRK inhibitor, Treatment of solid tumors0
European Federation of Medicinal Chemistry - XXVII International Symposium on Medicinal Chemistry (EFMC-ISMC 2022). Nice - September 4-8, 20220
Spesolimab. Anti-IL-36R monoclonal antibody, Treatment of generalized pustular psoriasis, Treatment of immune-mediated inflammatory diseases0
American Society of Nephrology's (ASN) Kidney Week - 2022 Annual Meeting. Orlando - November 3-6, 20220
Xeruborbactam. Ultrabroad-spectrum β-lactamase inhibitor, Treatment of bacterial infections0
American Society for Microbiology (ASM) Microbe – 2022 Annual Meeting. Washington, D.C. – June 9-13, 20220
Pozelimab/cemdisiran. Complement protein C5 inhibitor, Treatment of complement-mediated diseases0
Nafithromycin. Ketolide antibiotic, Treatment of community-acquired bacterial pneumonia0
Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2− and HER2+ advanced breast cancer0
Positioning of hafnium oxide nanoparticles therapy in cancer treatment0
European Association for the Study of Diabetes (EASD) – 58th Annual Meeting. Stockholm/Virtual – September 19-23, 20220
Pipeline on the Move0
0.10099196434021